Winter Park, Florida–(Newsfile Corp. – January 5, 2026) – Adia Nutrition Inc. (OTCQB: ADIA), an emerging leader in regenerative medicine through its subsidiary Adia Med, today announced that its patent-pending clinical study targeting Autism Spectrum Disorder (ASD) has gone live on ClinicalTrials.gov, marking a significant advancement in the company’s research pipeline.Clinical trial NCT07304440To view an enhanced version of this graphic, please…
